1. Sidaway, P. Low-grade glioma subtypes revealed. Nat Rev Clin Oncol 17, 335 (2020).
2. Pineros, M., Sierra, M.S., Izarzugaza, M.I. & Forman, D. Descriptive epidemiology of brain and central nervous system cancers in Central and South America. Cancer Epidemiol 44 Suppl 1, S141-S149 (2016).
3. Sturm, D., Pfister, S.M. & Jones, D.T.W. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. J Clin Oncol 35, 2370-2377 (2017).
4. Louis, D.N., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica 131, 803-820 (2016).
5. Renzi, S., et al. Causes of death in pediatric neuro-oncology: the sickkids experience from 2000 to 2017. J Neurooncol 149, 181-189 (2020).
6. Keshri, V., et al. Risk Stratification in Low Grade Glioma: A Single Institutional Experience. Neurol India 68, 803-812 (2020).
7. Viaccoz, A., Lekoubou, A. & Ducray, F. Chemotherapy in low-grade gliomas. Curr Opin Oncol 24, 694-701 (2012).
8. Ceccarelli, M., et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164, 550-563 (2016).
9. Louis, D.N., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131, 803-820 (2016).
10. Gesperger, J., et al. Improved Diagnostic Imaging of Brain Tumors by Multimodal Microscopy and Deep Learning. Cancers (Basel) 12(2020).
11. Ozcan, H., et al. A comparative study for glioma classification using deep convolutional neural networks. Math Biosci Eng 18, 1550-1572 (2021).
12. Mzoughi, H., et al. Deep Multi-Scale 3D Convolutional Neural Network (CNN) for MRI Gliomas Brain Tumor Classification. J Digit Imaging 33, 903-915 (2020).
13. Ning, Z., et al. Multi-modal magnetic resonance imaging-based grading analysis for gliomas by integrating radiomics and deep features. Ann Transl Med 9, 298 (2021).
14. Yang, Y., et al. Glioma Grading on Conventional MR Images: A Deep Learning Study With Transfer Learning. Front Neurosci 12, 804 (2018).
15. Li, Z., Wang, Y., Yu, J., Guo, Y. & Cao, W. Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma. Sci Rep 7, 5467 (2017).
16. Fukuma, R., et al. Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Sci Rep 9, 20311 (2019).
17. Chang, H., et al. Invariant delineation of nuclear architecture in Glioblastoma Multiforme for clinical and molecular association. IEEE Transactions on Medical Imaging 32, 670-682 (2013).
18. Chang, H., AD, B., Spellman, P. & Parvin, B. Classification of Tumor Histology via Morphometric Context. in IEEE Computer Vision and Pattern Recognition in press (2013).
19. Chang, H., et al. Morphometic analysis of TCGA glioblastoma multiforme. BMC Bioinformatics 12, 484 (2011).
20. Chang, H., et al. Stacked Predictive Sparse Decomposition for Classification of Histology Sections. Int J Comput Vis 113, 3-18 (2015).
21. Charles, N.A., Holland, E.C., Gilbertson, R., Glass, R. & Kettenmann, H. The brain tumor microenvironment. Glia 59, 1169-1180 (2011).
22. Mobadersany, P., et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proceedings of the National Academy of Sciences 115, E2970 (2018).
23. Zhang, L., et al. Genomic analysis of primary and recurrent gliomas reveals clinical outcome related molecular features. Sci Rep 9, 16058 (2019).
24. Petralia, F., et al. Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell 183, 1962-1985 e1931 (2020).
25. Wang, L., et al. Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer 20, 213 (2020).
26. Marabelle, A., et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21, 1353-1365 (2020).
27. Johnson, A., et al. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. Oncologist 22, 1478-1490 (2017).
28. Qi, Y., Liu, B., Sun, Q., Xiong, X. & Chen, Q. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. Front Immunol 11, 578877 (2020).
29. Fong, B., et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One 7, e32614 (2012).
30. Bettelli, E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
31. Khan, S., et al. Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance. Int J Mol Sci 21(2020).
32. Garrido-Navas, C., et al. Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents. Cells 8(2019).
33. Fujita, M., et al. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 16, 3409-3419 (2010).
34. Poli, A., et al. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget 4, 1527-1546 (2013).
35. Piñeiro-Yáñez, E., Jiménez-Santos, M.J., Gómez-López, G. & Al-Shahrour, F. In Silico Drug Prescription for Targeting Cancer Patient Heterogeneity and Prediction of Clinical Outcome. Cancers (Basel) 11(2019).
36. Wolchok, J.D., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15, 7412-7420 (2009).
37. McKenna, S.J., Ricketts, I.W., Cairns, A.Y. & Hussein, K.A. A comparison of neural network architectures for cervical cell classification. in 1993 Third International Conference on Artificial Neural Networks 105-109 (1993).
38. Yu, G., Wang, L.G., Han, Y. & He, Q.Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284-287 (2012).
39. Mayakonda, A., Lin, D.C., Assenov, Y., Plass, C. & Koeffler, H.P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28, 1747-1756 (2018).
40. Fan, Y., et al. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biol 17, 178 (2016).
41. Davoli, T., Uno, H., Wooten, E.C. & Elledge, S.J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355(2017).
42. Jiménez-Sánchez, A., Cast, O. & Miller, M.L. Comprehensive Benchmarking and Integration of Tumor Microenvironment Cell Estimation Methods. Cancer Res 79, 6238-6246 (2019).
43. Şenbabaoğlu, Y., et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol 17, 231 (2016).